Lu 177 ethylenedicysteine amifostine / Cell-Point - LARVOL DELTA

ASCO 2022: Latest in prostate cancer, including PARP inhibitors (ecancer) - "...Prof Eleni Efstathiou...discuss the latest in prostate cancer, including PARP inhibitors. Initially, they discuss the latest trials and updates in prostate cancer including PROPEL, MAGNITUDE and the ARCHES trial."

Video

Practice-Changing Data From 2021 Sets Tone for New Year (OncLive) - '"Looking at immunotherapy for patients with completely resected NSCLC after chemotherapy and immunotherapy has been a transformative treatment for metastatic lung cancer,' said Stephen V. Liu, MD. 'We also know that for patients with resected lung cancer, while our goal is cure, it's not always our expectation. Lung cancer is a very difficult disease to eradicate'...The relapse rate for patients treated with curative intent is approximately 60%, and for those treated earlier in their disease course, immunotherapy may reduce incidence of recurrence."

Media quote